Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - shares
Oct. 11, 2022
Oct. 11, 2022
Subsequent Events (Details) [Line Items]    
Issued and outstanding equity interests percentage   100.00%
Subsequent event, description   The Company acquired all issued and outstanding equity interests of AlloMek in exchange for: (i) an aggregate of 2,700,000 shares of the Company’s common stock, par value $0.0001 per share, (ii) an aggregate of 1,000,000 warrants to purchase shares of the Company’s Common Stock at an exercise price of $1.88 per share, which may be exercised on a cashless basis, for a period of five years commencing on the date of issuance, (iii) a cash payment in the amount of $1,050,000, (iv) the right to certain milestone payments in an amount up to $5,000,000, and (v) the right to contingent earn-out payments ranging from 3% to 5% of net sales of the Drug depending on the amount of such net sales in the applicable measurement period.
Restricted shares 1,350,000  
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures 112,500